LSZ: Difference between revisions
No edit summary |
No edit summary |
||
| Line 23: | Line 23: | ||
= Harm Reduction = | = Harm Reduction = | ||
While widespread use of LSZ is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to [[LSD]]. Refer to [[LSD]] and [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for more information. | |||
= Legal status = | = Legal status = | ||
Revision as of 13:32, 14 July 2014
LSZ, also known as Lysergic acid 2,4-dimethylazetidide, is a hallucinogenic drug and an analogue of LSD developed by the team led by David E. Nichols at Purdue University. While LSZ has subtly different effects than LSD, it appears to be slightly longer lasting and slightly more potent.
Dosage
Light: 100-150 μg
Common: 150-300 μg
Strong: 300+ μg
Duration
Onset: 90-120 minutes
Total: 7-10 hours
Effects
While LSD has subtly different effects than LSD, it appears to be slightly longer lasting while also having a longer comeup.
Harm Reduction
While widespread use of LSZ is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to LSD. Refer to LSD and Psychedelic Harm Reduction for more information.
Legal status
America
Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.